Word: stockings
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
QUESTION 6: You've almost hit the big time! But internal dissension is tearing your company apart. Specifically, your employees are sick of working for free. How do keep morale up without actually paying wages? A) Promise to distribute even more non-existent stock options; B) Give them all a business cards and a "Chief (blank) Officer" title; C) Beer; D) Screw it. Dump those deadweights and poster the campus, advertising your new "comp...
...Internet startup founder like yourself has a bright future. What is your exit strategy? A) Corporate buy-out. Earn a six-figure salary as CEO, hire a manager, dump your equity and spend the rest of your days playing Microsoft Golf 2000; B) IPO. Drum up hype, watch your stock price sky rocket, dump your equity and move to Vegas; C) Consolidate ownership. Convince your partners that the company is on the fast track to success, confess you are not the most qualified leader, sell your equity (for a reasonable price that includes "future earnings"), and go to law school...
...stock you bought dropped 30% yesterday because it failed to meet Wall Street's exacting expectations. Ouch--you've just been scalded by what we call an earnings blow-up. Now what? Do you lie there inert, screaming "Where's the rest of my stock?" Nah. In the trenches of capitalism where I toil, one of these high-explosive blow-ups hits me monthly, obliterating any hope of a quick profit, or perhaps producing a staggering unrealized loss. IBM, Xerox, Unisys and Lexmark have all detonated recently. First, take heart. You aren't the only one dumb enough...
...that inhibit the growth of new capillaries. The idea behind this new class of drugs is that tumors cannot grow bigger than a few hundred thousand cells--about the size of a peppercorn--without growing their own blood-supply system. Researchers and patients, not to mention the owners of stock in half a dozen biotech companies, are eagerly awaiting results of clinical trials of antiangiogenic factors, which might be used in combination with chemotherapy to knock down big tumors and then prevent any surviving tumors from growing enough to do further damage...
...panic. That's TIME Digital editor Josh Quittner's advice to Microsoft investors Monday, as the stock price fell 5 percent in the first hour of trading following last Friday's antitrust case setback. (It later recovered to 89.93, and finished down just 1.8 percent on the day.) "Microsoft is the same company it ever was - one of the greatest concentrations of brainpower on the planet," says Quittner. "That's not going to change, and the company shouldn't be worth any less Monday than it was on Friday. Moreover, most investors had good reason to expect this ruling." Judge...